- Home
- TVRD vs ANTX Comparison
TVRD vs ANTX Comparison
Compare TVRD & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TVRD | ANTX |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.1M | 36.7M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | TVRD | ANTX |
|---|---|---|
| Price | $3.87 | $5.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $51.67 | $2.00 |
| AVG Volume (30 Days) | 37.0K | ★ 3.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.50 | $1.00 |
| 52 Week High | $43.65 | $6.91 |
Technical Indicators
Market Signals| Indicator | TVRD | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.01 | 86.63 |
| Support Level | $3.81 | $1.05 |
| Resistance Level | $4.45 | N/A |
| Average True Range (ATR) | 0.21 | 0.68 |
| MACD | 0.01 | 0.46 |
| Stochastic Oscillator | 38.12 | 71.28 |
Price Performance
Historical ComparisonAbout TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.